MSB Trading - 2020, page-21820

I wanted to share some outstanding news folks:

As many of you already know, I had lamented about dismal institutional holding of MESO (ADRs). It was 2.1% as of the end of first quarter 2020 (first Q in the US is Jan, Feb and March).
Institutional ownership means a conviction in the company and it's future growth and more importantly, it means the number of shares traded in and out on a short term basis is greatly reduced. Institutional owners do careful due diligence before buying shares. The greater the institutional ownership percentage in a company, the stronger the stability and growth prospects.

Since I wasn't able to get any response from Mesoblast US IR, I took it upon myself to do some research. Spent a few hours and this is what I came up with:
Ok, so on 07/24/2020, Fidelity Select Biotechnology Portfolio (FBIOX) reported they purchased 2,182,670 shares of MESO. These are ADRs so the purchase was in USD.
2,182,670 ADRs equates to 10,913,350 of MSB shares. Would you say that's a nice chunk?
So what this means is Fidelity Select Biotechnology Portfolio (FBIOX) added MESO to their Select Biotechnology Portfolio as a new position.

Fidelity Select Biotechnology Portfolio (FBIOX) has current net assets of about $8 Billion USD and has 91% of its allocation to biotechnology stocks. Here is the allocation breakdown:

Sub-Industry

Diversification

AS OF 6/30/2020

Portfolio Weight

Biotechnology

90.67%

Pharmaceuticals

6.20%

Other Diversified Financial Services

1.02%

Life Sciences Tools & Services

0.53%

Health Care Equipment

0.26%

Health Care Technology

0.24%

Asset Management & Custody Banks

0.03%

Personal Products

0.00%

Health Care Services

0.00%

Top ten holdings are:

35.90% of Total Portfolio

ABBVABBVIE INC

REGNREGENERON PHARMACEUTICALS INC

AMGNAMGEN INC

SGENSEATTLE GENETICS INC

ALNYALNYLAM PHARMACEUTICALS INC

IMMUIMMUNOMEDICS INC

BMRNBIOMARIN PHARMACEUTICAL INC

SRPTSAREPTA THERAPEUTICS INC

XLRNACCELERON PHARMA INC

NBIXNEUROCRINE BIO

As you can see, Mesoblast is in elite company. I hope to see Mesoblast make it to the top ten soon.

But wait, there's more!

Besides Fidelity Select Biotechnology Portfolio (FBIOX), the following are other institutions that have added to their MESO (ADR) holdings in the 2nd Quarter 2020 - again, this is all in the US, in US dollars.

The following INCREASED their positions:
SCHC - Schwab International Small-Cap Equity ETF
DFA INVESTMENT DIMENSIONS GROUP INC
International Vector Equity Portfolio Shares
VTMGX - Vanguard Developed Markets Index Fund Admiral Shares
AZL DFA International Core Equity Fund
Renaissance Technologies LLC
Morgan Stanley
Bank of America
AVDE - Avantis International Equity ETF
Goldman Sachs Motif Human Evolution ETF
Wilbanks Smith & Thomas Asset Management Llc
Hudson Canyon Investment Counselors Llc
Group One Trading, L.p.
AVDE - Avantis International Equity ETF
Goldman Sachs Motif Human Evolution ETF
Wilbanks Smith & Thomas Asset Management Llc
Hudson Canyon Investment Counselors Llc
Group One Trading, L.p.

The following OPENED NEW positions:
SG Americas Securities, LLC
Parallel Advisors, LLC
JSCGX - Jacob Small Cap Growth Fund Investor Class
JMCGX - Jacob Micro Cap Growth Fund Investor Class
OWSMX - Old Westbury Small & Mid Cap Strategies Fund
Advisor Group Holdings, Inc.
Marshall Wace LLP
Citadel Advisors LLC
Millennium Management Llc
US Bancorp
Bank Julius Baer & Co. Ltd, Zurich
Cetera Advisor Networks LLC
Aperio Group, LLC
Lindbrook Capital, Llc
Ingalls & Snyder Llc

NOTE: The latest NASDAQ report of institutional holdings for the 2nd Quarter may not yet reflect the above changes.

PS: Lately, there have been some Yahoo posters who have been plagiarizing my posts by posting them on the Yahoo board. I want to make it clear that I do NOT post on the Yahoo board. When I look there on occasion, I noticed that at least one poster "MarketMania" has posted my posts without citation. This does not bother me but I just want to make it clear that I do NOT post on the Yahoo board.